Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012601 | 0.88 | PDE4B (0.33) | — | |
| SCHEMBL6043997 | 0.84 | NPC1 (0.33) | CHRM4CHRM5CHRM1 | |
| SCHEMBL6043619 | 0.81 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL17672833 | 0.79 | — | — | |
| SCHEMBL3603211 | 0.79 | PDE4B (0.35) | CHRM1SMN1; SMN2 | |
| SCHEMBL2012231 | 0.78 | — | — | |
| SCHEMBL2562675 | 0.76 | CARM1 (0.33) | — | |
| SCHEMBL6044711 | 0.76 | NPC1 (0.31) | — | |
| SCHEMBL1463586 | 0.76 | PDE4B (0.34) | PDE4DALDH1A1 | |
| SCHEMBL28696295 | 0.75 | CHRM2 (0.40) | CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1886378-A | 1,4-disubstituted isoquinilone derivatives as RAF-kinase inhibitors useful for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2006-12-27 | — | — | CN | claimed |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| CN-107266421-A | Substituted benzimidazoles derivative | 正大天晴药业集团股份有限公司 | 2017-10-20 | — | — | CN | disclosed |
| CN-102892415-B | For treating and preventing Fe (III) the coordination compound compound of iron deficiency symptom and iron deficiency anemia | 维福（国际）股份公司 | 2016-10-19 | — | — | CN | disclosed |
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9096591-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034880-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8999978-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| CN-1206219-C | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2005-06-15 | — | — | CN | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| CN-1545501-A | Novel cyclohexyl sulphones | Ĭ�ˡ�����-��ķ��˾ | 2004-11-10 | — | — | CN | disclosed |
| CN-1543455-A | 3-phenoxy-4-pyridazinol derivatives and herbicidal compositions containing the same | 三共农业株式会社 | 2004-11-03 | — | — | CN | disclosed |
| CN-1136191-C | Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists | ������ҩ������˾ | 2004-01-28 | — | — | CN | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| JP-2003040892-A | RUTHENIUM PHTHALOCYANIN DERIVATIVE AND METHOD OF PRODUCING THE SAME | AISIN SEIKI CO LTD | 2003-02-13 | — | — | JP | disclosed |
| CN-1301253-A | Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists | AVENTIS PHARMACEUTICAL INC (US) | 2001-06-27 | — | — | CN | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | CHRM4 4870/4885CHRM5 4883/4885CHRM1 4878/4885 |
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | CHRM4 101/4885CHRM5 98/4885CHRM1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.